uniQure N.V. (QURE) Stock: Slips After $225 Million Public Offering Pricing

TLDR

• uniQure slipped 0.90% to $48.60 after pricing its public offering.
• QURE priced 4.95 million ordinary shares at $45.50 each.
• The offering may raise $225 million before fees and expenses.
• Underwriters can buy 741,758 extra shares within 30 days.
• Fresh capital supports uniQure while new share supply weighs.

uniQure N.V. (QURE) shares fell 0.90% to $48.60 after the company priced a large public stock offering. QURE traded unevenly during the session and briefly climbed above $49.90 before losing momentum. The financing strengthens uniQure’s cash position, although the new shares increase its outstanding equity.

uniQure N.V., QURE

uniQure Prices Offering Below Market Level

uniQure priced 4,945,055 ordinary shares at $45.50 each through an underwritten public offering. The offering price sits below QURE’s current market price of $48.60. Consequently, the pricing created pressure as traders assessed the potential dilution from the new shares.

The company expects approximately $225 million in gross proceeds before fees, commissions, and other offering expenses. uniQure will sell all shares included in the transaction and retain the resulting proceeds. The company has not provided net proceeds after accounting for the transaction’s associated costs.

The offering could close on or around June 25, subject to standard closing requirements. Therefore, the transaction remains dependent on the completion of customary legal and administrative procedures. The short completion schedule gives uniQure quick access to additional capital after pricing the shares.

Underwriter Option Could Increase Proceeds

uniQure granted the underwriters a 30-day option covering another 741,758 ordinary shares. The banks may purchase those shares at $45.50 each, less underwriting discounts and commissions. If fully exercised, the option could add about $33.8 million in gross proceeds.

As a result, total gross proceeds could rise to approximately $258.8 million with the additional shares. However, the base transaction remains valued at about $225 million before expenses. The expanded offering would also create further dilution by increasing the number of shares sold.

Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets serve as joint bookrunning managers. Meanwhile, H.C. Wainwright acts as the offering’s lead manager. These firms will coordinate distribution and manage the sale under the agreed underwriting terms.

Financing Follows Gene Therapy Progress

uniQure develops gene therapies for severe diseases with limited treatment choices. The company’s programs include therapies targeting Huntington’s disease and other serious neurological conditions. Therefore, clinical research and regulatory work require continued funding across several development stages.

The company recently reported regulatory progress involving its lead Huntington’s disease gene therapy program. That update drove a sharp rise in QURE shares before the latest offering announcement. The capital raise allows uniQure to strengthen its finances following that significant market move.

uniQure filed the offering through an automatically effective shelf registration statement submitted in January 2025. It also filed a preliminary prospectus supplement with the SEC on June 22, 2026. The company will submit the final prospectus supplement containing the offering’s completed terms.

QURE Stock Pulls Back After Intraday Spike

QURE shares showed wide intraday swings as the market processed the discounted offering price. The stock briefly moved above $49.90 but failed to maintain that advance. It later stabilized near $48.60, representing a 0.90% decline during the reported session.

The market price remained $3.10 above the offering price despite the daily pullback. That difference reflected continued support following uniQure’s recent clinical and regulatory developments. The offering added new supply and limited the stock’s intraday gains.

The financing gives uniQure more capital to support operations and advance its development pipeline. At the same time, shareholders face dilution from almost five million newly issued ordinary shares. The balance between stronger liquidity and additional equity supply shaped QURE’s latest price movement.

The post uniQure N.V. (QURE) Stock: Slips After $225 Million Public Offering Pricing appeared first on CoinCentral.